Drugs / BI 811283
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00701324 | Jun 2007 → May 2011 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00632749 | May 2008 → Mar 2014 | acute myeloid leukemia | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 811283 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00632749 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL3545395 ↗1“Aurora B kinase inhibitor BI 811283” PMID 30450591 ↗ Nov 2018 |
| Route | Intravenous | “BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle” NCT00632749 ↗ |
| Target | AURKB | “Serine/threonine-protein kinase Aurora-B inhibitor” CHEMBL3545395 ↗ |